KT Irfan first Indian athlete to qualify for Tokyo 2020

New Delhi, Jan 2: Thrilled after getting to know about Hardik Pandya and Natasa Stankovic's engagement, skipper Virat Kohli on Wednesday called it a "pleasant surprise".

Extending his best wishes to the newly-engaged couple, Kohli posted a comment on Pandya's Instagram post which read, "Congratulations H. What a pleasant surprise. Wish you guys great times ahead. God bless".

On the first day of the New Year 2020, Pandya announced his engagement with Serbian actor Natasa Stankovic.

The cricketer took to Instagram to share the photo with the actor and captioned the post: "Mai tera, Tu meri jaane, saara Hindustan. 01.01.2020 #engaged".

The couple got engaged in Dubai and were seen taking a ferry ride along with close friends.

On the work front, Stankovic was last seen in a song from the Bollywood movie The Body starring Emraan Hashmi and Rishi Kapoor. She had also made it to the finals of the TV show Nach Baliye with her ex-boyfriend Aly Goni.

Stankovic first became a household name after appearing as a contestant on famous reality show Bigg Boss 8.

In 2019, the Board of Control for Cricket in India (BCCI) had confirmed that Pandya had had lower-back surgery in London.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.